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To the Editor: Class D OXA 
β-lactamases are characterized as pen-
icillinases that can hydrolyze oxacillin 
and cloxacillin and are poorly inhib-
ited by clavulanic acid and EDTA. 
OXA-48 is one of the few members of 
this family to possess notable carbap-
enem-hydrolyzing activity (1). First 
described in 2004 in Turkey, OXA-48 
has recently started to spread in Europe 
and the Middle East (2). We report the 
recent emergence of the plasmid-en-
coded blaOXA-48 gene in multidrug-re-
sistant  Enterobacteriaceae recovered 
from patients in Dakar, Senegal, in 
hospitals and in the community. 
From November 2008 through 
October 2009, 11 Enterobacteriaceae 
isolates (8 Klebsiella pneumoniae, 1 
Escherichia coli, 1 Enterobacter cloa-
cae, and 1 Enterobacter sakazakii) 
with reduced susceptibility to imipen-
em were identiﬁ  ed at the Institut Pas-
teur (Dakar, Senegal). Antibacterial 
drug susceptibility was determined 
by the disk diffusion method and in-
terpreted according to the European 
Committee on Antimicrobial Suscep-
tibility Testing guidelines (www.eu-
cast.org). Nine isolates were resistant 
to expanded-spectrum cephalosporins 
and also to other antibacterial drug 
classes.
The isolates were recovered from 
6 patients with urinary tract infections, 
4 patients with surgical infections, and 
1 patient with omphalitis. Nine infec-
tions were hospital acquired (Le Dan-
tec and Principal Hospitals). Because 
the patients died before antibacterial 
drug susceptibility testing could be 
completed, all 5 patients with surgical 
infections or omphalitis received only 
empirical therapy with amoxicillin/
clavulanate. One patient with a noso-
comial urinary tract infection caused 
by a co-trimoxazole–susceptible strain 
was successfully treated with this an-
tibacterial agent. The antibacterial 
drug regimens of the remaining 4 pa-
tients were not known, and they were 
lost to follow-up. We determined the 
MICs of imipenem, meropenem, and 
ertapenem by using the Etest method 
(AB Biodisk, Solna, Sweden), which 
showed that 9 isolates were suscep-
tible to imipenem and meropenem 
but either intermediately susceptible 
or resistant to ertapenem (Table). The 
2 imipenem-nonsusceptible isolates 
were susceptible or intermediately 
susceptible to meropenem, and both 
were resistant to ertapenem. 
We used previously described   
PCRs (1,3–7) to screen for carbap-
enem-hydrolyzing β-lactamase genes 
(blaVIM, blaIMP, blaKPC, and blaOXA-48), 
as well as plasmid-encoded blaCTX-M, 
blaAmpC, blaOXA-1, and blaTEM  β-lactamase 
genes; the aac(6′)-Ib aminoglycoside 
resistance gene; the quinolone resis-
tance genes qnrA,B,S; the tetracycline 
resistance genes tetA,B,D; and class 
1 integron. The blaOXA-48,  blaCTX-M, 
blaAmpC, and aac(6′)-Ib genes and the 
variable region of class 1 integron 
were then characterized by direct 
DNA sequencing of the PCR products. 
blaOXA-48 was present in all 11 isolates. 
blaVIM, blaIMP, and blaKPC were not de-
tected. The qnr genes were present in 
7 isolates resistant to ciproﬂ  oxacin. 
The aac(6′)-Ib-cr variant was present 
in 7 isolates resistant to gentamicin, 
tobramycin, and ciproﬂ  oxacin.
The 9 isolates resistant to expand-
ed-spectrum cephalosporins all har-
bored the blaCTX-M-15 gene. The E. coli 
isolate also harbored the plasmid-en-
coded blaAmpC gene ACT-1; blaCTX-M-15, 
blaOXA-1, blaTEM, and aac(6′)lb-cr were 
associated in 6 isolates. Long-range 
PCRs showed that these latter 4 genes 
were located in the same “multidrug 
resistance region,” as described in Sen-
egal (6). Positive conjugation experi-
ments with sodium azide–resistant E. 
coli J53 showed through PCR results, 
plasmid DNA extraction, and antibio-
gram patterns of the obtained transcon-
jugants that blaOXA-48 was located on a 
70-kb self-conjugative plasmid. 
The genetic environment of 
blaOXA-48 was then investigated by PCR 
with primers speciﬁ  c for insertion se-
quence IS1999 and for the 5′ part of 
blaOXA-48 (1). blaOXA-48 was found to be 
part of a Tn1999 composite transposon 
composed of 2 copies of the insertion 
sequence IS1999, as reported (2). Fur-
ther sequencing of the IS1999 located 
upstream of blaOXA-48 showed that it 
was consistently truncated by the in-
sertion sequence IS1R, as initially de-
scribed in Turkey and more recently in 
Lebanon and Egypt (2,8).
XbaI pulsed-ﬁ  eld gel electropho-
resis was then used to study the genet-
ic relatedness of the 8 K. pneumoniae 
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isolates. Three isolates had similar 
restriction proﬁ  les and had been re-
covered from 3 patients concurrently 
hospitalized at Le Dantec Hospital, 
suggesting nosocomial transmission. 
A class 1 integron harboring the dfrA1 
trimethoprim-resistance gene was de-
tected in the 3 clonal isolates.
Together, these ﬁ  ndings show the 
recent emergence of blaOXA-48 in Sene-
gal in community and hospital settings. 
They may also suggest the spread of 
the same major carrying plasmid be-
tween the Middle East and Africa. 
Although 9 of the 11 isolates were 
found to be susceptible to imipenem 
on the basis of their MICs, their MICs 
were nonetheless higher than those of 
blaOXA-48–negative isolates. This raises 
2 issues. First, these strains might go 
undetected during routine antibacte-
rial drug susceptibility testing, a prob-
lem that could be overcome by using 
ertapenem, a compound more suscep-
tible to carbapenemases. Second, the 
clinical efﬁ  cacy of imipenem on such 
strains is uncertain. The frequency 
of acquired carbapenemases, which 
emerged early after imipenem intro-
duction in Senegal (2008), is probably 
strongly underestimated, partly owing 
to the limited availability of reliable 
clinical laboratories (9). Because mul-
tidrug resistance is prevalent among 
Enterobacteriaceae isolated in Dakar 
hospitals (B. Garin, unpub. data) and 
in rural communities (6), the emer-
gence of blaOXA-48 is a clear cause for 
concern.
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Table. Resistance genes and carbapenem MICs of 11 Enterbacteriaceae isolates, Senegal, 2008–2009* 
Isolate Species Origin† 
Resistance genes  MIC (μg/mL) 
blaOXA-48 blaCTX-M-15 blaOXA-1 blaTEM aac-6ƍ-Ib qnr tet dfr IPM MEM ERT
17176  Klebsiella pneumoniae  1+ + – –– – A,D – 1 0.38 1.5
22184  K. pneumoniae‡2  + + + + cr S A A1 1 0.38 1.5
20254  K. pneumoniae‡3  + ++ + cr S A A1 1 0.38 1.5
10243  K .pneumoniae‡3  + ++ + cr S A A1 1 0.38 1.5
19220  K. pneumoniae 2+ ++ + cr B A,D – 0.5 0.19 0.75
18212  K. pneumoniae 2+ –– – – – – – 3 2 1 2
18220  K. pneumoniae 3+ + – +– SD – 1 0.38 1.5
06003  K. pneumoniae 4+ – – – – – – – 2 0.25 0.75
HPD Enterobacter cloacae 3+ ++ + cr B,S B –438
20247  Enterobacter sakazakii 5+ ++ + cr –– –0 . 51 3
24246  Escherichia. coli 4+ ++ – cr S –– 2 0 . 5 2
J53 E. coli – – – – – – – – 0.12 0.03 0.03
TC  E. coli + – – – – – – – 0.5 0.19 0.75
*IPM, imipenem; MEM, meropenem; ERT, ertapenem; TC, transconjugants. 
†Origin: 1, postsurgical visceral infection; 2, postsurgical orthopedic infection; 3, nosocomial urinary tract infection; 4, community-acquired urinary tract 
infection; 5, omphalocele infection.  
‡Clonally related isolates. 